Genenta Science Transforms into Saentra Forge, Focuses on Biotech and Defense Acquisitions
Genenta Science S.p.A. is rebranding as Saentra Forge S.p.A. and shifting its focus towards acquisitions in the national-security sector, aiming for majority stakes in profitable companies. The initial integration will be with defense-sector firm ATC, while the Praexidia Foundation will enhance governance and support acquisition strategies. The company anticipates an increase in cash and marketable securities to approximately $33 million by December 31, 2025, following a direct offering, with shareholder approval for the name change and new Nasdaq ticker SAEN set for March 25-26, 2026.
Theia Market Signal Identification - AI Assisted
Genenta Science S.p.A. is undergoing a strategic transformation to become Saentra Forge S.p.A., targeting acquisitions in national-security sectors under Italian Golden Power legislation. The company aims for majority ownership in profitable businesses generating up to €5 million in EBITDA.
The first integration is with ATC, a defense-sector company. Praexidia Foundation joins as a long-term shareholder, enhancing governance and supporting acquisition strategies. The company has achieved clinical milestones to advance its cell therapy platform and is engaging with pharmaceutical partners to enhance market access.
As of December 31, 2025, cash and marketable securities are expected to be approximately $33 million, an increase from $17.7 million in June 2025, attributed to a direct offering. Shareholder approval for the name change and new Nasdaq ticker SAEN is scheduled for March 25-26, 2026.
Comments